Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden flag Sweden · Delayed Price · Currency is SEK
11.70
+0.05 (0.43%)
May 21, 2026, 1:13 PM CET

Xbrane Biopharma AB Cash Flow Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
106.01127.24-266.22-388.17-172.51-188.38
Depreciation & Amortization
7.829.9824.2121.4316.5812.22
Other Operating Activities
-327.89-311.55190.93145.36-7.25-5.04
Change in Accounts Receivable
37.2270.03-4.56-85.131.7-61.09
Change in Inventory
10.9548.98-166-56.6-50.26-
Change in Accounts Payable
159.93--22.57--
Change in Other Net Operating Assets
-368.78-368.78212.82-17.8322.67
Operating Cash Flow
-190.55-250.69-133.73-406.68-193.92-219.61
Capital Expenditures
---0.5-6.79-11.62-27.68
Sale (Purchase) of Intangibles
-126.55-139.64-51.75-9.98-48.51-49.67
Other Investing Activities
102.5102.5----
Investing Cash Flow
-24.05-37.14-52.25-16.77-60.13-77.35
Long-Term Debt Issued
-77.670225--
Long-Term Debt Repaid
--47.78-126.14-34.74-8.34-7.27
Total Debt Repaid
-21.09-47.78-126.14-34.74-8.34-7.27
Net Debt Issued (Repaid)
36.5129.82-56.14190.26-8.34-7.27
Issuance of Common Stock
240240337.24120.02170.55380.87
Other Financing Activities
-14.17-14.22-37.48-11.58-13.35-24.23
Financing Cash Flow
262.34255.61243.62298.7148.86349.37
Foreign Exchange Rate Adjustments
-5.9-6.050.84-4.494.051.39
Miscellaneous Cash Flow Adjustments
0.190.530.440.64-0.05-1.76
Net Cash Flow
42.04-37.7458.93-128.59-101.1952.04
Free Cash Flow
-190.55-250.69-134.23-413.47-205.53-247.29
Free Cash Flow Margin
-249.23%-164.55%-90.64%-173.20%-356.72%-2309.16%
Free Cash Flow Per Share
-9.25-15.25-13.64-1800.48-1004.76-1310.16
Cash Interest Paid
5.485.4817.657.582.592.64
Cash Income Tax Paid
0.09-----
Levered Free Cash Flow
-246.01-347.0110.32-244-169.78-279.72
Unlevered Free Cash Flow
-242.38-339.4929.46-232.43-168.17-278.07
Change in Working Capital
-160.69-249.7742.27-119.16-30.73-38.42
Source: S&P Global Market Intelligence. Standard template. Financial Sources.